[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Kiran KU, Krishna Moorthy KV, Meher V, Rao PN: Relapse of leprosy presenting as nodular lymph node swelling. Indian J Dermatol Venereol Leprol; 2009 Mar-Apr;75(2):177-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of leprosy presenting as nodular lymph node swelling.
  • Lymphadenopathy is known to be associated with lepromatous leprosy and has also been observed as a feature of type-2 lepra reaction.
  • However, nodular lymph node enlargement is not commonly reported in leprosy patients or as a feature of relapse.
  • We herewith are presenting a case of bacteriological relapse in a patient of lepromatous leprosy treated 22 years before till smear negativity with WHO multidrug therapy (MDT) multibacillary type (MB).
  • She presented with prominent nodular swelling of the cervical group of lymph nodes along with generalized lymphadenopathy, which was mistakenly treated as tubercular lymphadenopathy.
  • A diagnosis of late bacteriological relapse of lepromatous leprosy presenting with prominent lymphadenopathy and ENL was made after relevant investigations.
  • The patient was started on treatment with WHO MDT MB (daily dapsone and clofazimine and monthly rifampicin) and thalidomide (200 mg/day).
  • Nerve pain regressed within 2 weeks of therapy.
  • The lymph nodal swelling regressed within 3 months of starting treatment.
  • [MeSH-major] Leprosy / diagnosis. Leprosy / prevention & control. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / prevention & control
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Leprostatic Agents / therapeutic use. Lymphatic Diseases / diagnosis. Lymphatic Diseases / drug therapy. Lymphatic Diseases / prevention & control. Secondary Prevention

  • MedlinePlus Health Information. consumer health - Mycobacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19293508.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Leprostatic Agents
  •  go-up   go-down


2. Falchi L, Capello D, Palumbo B, Rauco A, Emili R, Cianciulli M, Pace R, Capparella V, Liberati F, Liberati AM: A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy. Eur J Haematol; 2007 Nov;79(5):455-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.
  • We report the case of an Epstein-Barr virus (EBV)- and human immunodeficiency virus-serum negative patient suffering from repeatedly relapsing classical Hodgkin's Lymphoma (cHL) associated with a histological picture of plasma cell-hyaline vascular (PC-HV) form of Castleman's disease (CD).
  • Single-strand polymerase chain reaction failed to detect human herpesvirus 8 or EBV in the involved tissues.
  • At the time of second relapse in July 2005, the clinical picture was characterized by a palpable right hypogastric mass, disclosed at physical exam, in the absence of other enlarged peripheral lymph nodes, subjective symptoms or laboratory profile alterations.
  • Combined hybrid-(18)F-fluorodeoxyglucose positron emission-computerized tomography (18F-FDG PET/CT) showed increased radionuclide uptake in multiple external iliac lymph nodes [standardized uptake value (SUV) of 7.4] and non-palpable left supraclavicular lymph nodes (SUV of 5.8).
  • Because of uncertain persistent disease in the supraclavicular nodal site, involved-field radiotherapy (RT) was delivered in that area as consolidation treatment.
  • This case is in concordance with previously published data suggesting that rituximab immunotherapy might be a valid option in the treatment of CD and also have a role in the management of relapsing cHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Giant Lymph Node Hyperplasia / complications. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Hyalin / metabolism. Immunologic Factors / therapeutic use. Plasma Cells
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Chemotherapy, Adjuvant. Female. Fluorodeoxyglucose F18. Humans. Positron-Emission Tomography. Radiopharmaceuticals. Radiotherapy, Adjuvant. Recurrence. Rituximab. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Castleman's Disease.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2003 Jun 13;17(9):1409-10 [12799570.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]
  • [Cites] AIDS. 2004 Feb 20;18(3):585-6 [15090823.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1939-41 [15223659.001]
  • [Cites] Blood. 1991 Jun 1;77(11):2413-8 [1710152.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):602-5 [8302342.001]
  • [Cites] Arch Pathol Lab Med. 1996 Jan;120(1):91-6 [8554455.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):569-71 [8652374.001]
  • [Cites] AIDS. 1996 Aug;10(9):941-9 [8853726.001]
  • [Cites] J Pathol. 1997 Sep;183(1):44-50 [9370946.001]
  • [Cites] Br J Haematol. 1999 Mar;104(3):482-5 [10086783.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):302-5 [15795923.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2627-32 [15998837.001]
  • [Cites] Eur J Haematol. 2006 Feb;76(2):119-23 [16405432.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):882-8 [10843293.001]
  • [Cites] Head Neck. 2001 Feb;23(2):166-9 [11303634.001]
  • [Cites] J Clin Pathol. 2001 Oct;54(10):790-1 [11577129.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3473-5 [11719390.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):1-5 [11815953.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):119-26 [11835348.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):310-4 [12872350.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2786-8 [12842986.001]
  • (PMID = 17908180.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2121125
  •  go-up   go-down


3. Zhang HY, Liu AL, Zhou LS, He MX, Wang JX: Primary cutaneous marginal zone B-cell lymphoma with amyloid deposition: report of two cases with review of literature. Chin J Cancer; 2010 Jun;29(6):634-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous marginal zone B-cell lymphoma with amyloid deposition: report of two cases with review of literature.
  • If there was a great amount of amyloid depositions in the skin tissue, it would be considered to be amyloid deposition disease at first, and then primary cutaneous marginal zone B-cell lymphoma (PCMZL).
  • Three years after the initial diagnosis, he developed recurrences on the right para-auxillary that was still diagnosed with "probably amyloidosis".
  • Microscopically, the tumors of both cases were located in dermis and subcutaneous, tumor cells were medium size with a nodular or diffuse distribution, and some of tumor cells were plasmacytoid/plasma cells.
  • Congo red staining showed positive of amyloid deposition in tumor tissues of both cases.
  • The patients with PCMZL should undergo regular examinations and chemotherapy as well as a long-term follow-up since it is apt to recur or relapse.
  • [MeSH-major] Amyloidosis / pathology. Head and Neck Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, CD / metabolism. Antigens, CD45 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Elbow. Follow-Up Studies. Humans. Interferon Regulatory Factors / metabolism. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Prednisone / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507739.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.1.3.48 / Antigens, CD45; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


Advertisement
4. Grogg KL, Jung S, Erickson LA, McClure RF, Dogan A: Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol; 2008 Jun;21(6):708-15
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior.
  • Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, a provisional entity in the 2005 WHO-EORTC classification for cutaneous lymphomas, is not well characterized.
  • Histologically, the infiltrate showed a nodular pattern in the dermis and subcutis without epidermotropism, and had a polymorphous composition with a predominance of small to medium-sized CD4-positive T cells.
  • The majority resolved without relapse, one without treatment, four with excision, and four with radiation therapy.
  • One patient developed local recurrence.
  • The patient with multiple lesions had disease progression despite chemotherapy and stem cell transplant.
  • In patients with isolated cutaneous lesions, the indolent behavior of this rare T-cell neoplasm should be recognized to avoid unnecessary treatment.
  • [MeSH-major] CD4-Positive T-Lymphocytes / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. History, 17th Century. Humans. Immunohistochemistry. Lymphoma, B-Cell / pathology. Male. Middle Aged. Mycosis Fungoides / pathology. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18311111.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. van Grotel M, Lam KH, de Man R, Beishuizen A, Pieters R, van den Heuvel-Eibrink MM: High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only. Leuk Lymphoma; 2006 Aug;47(8):1504-10
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
  • Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare variant of Hodgkin's lymphoma (HL) in children.
  • Since specific immunohistochemical staining has become available, NLPHL can be separated from classical Hodgkin's lymphoma (cHL) more accurately.
  • Scarce information is available about pediatric NLPHL treated with chemotherapy only.
  • Therefore, clinical characteristics, treatment, response and outcome of seven pediatric NLPHL patients, median age 9.2 years (range 7.5 - 14.2 years), diagnosed between 1986 - 2003 among 58 HL patients, uniformly treated in a single center with chemotherapy only, were evaluated.
  • The median follow-up time was 4.2 years (range 2.1 - 10.2 years).
  • Upfront treatment of NLPHL patients consisted of six courses of epirubicin, bleomycin, vinblastine and dacarbazine (EBVD) without radiotherapy, whereas cHL patients received six courses of EBVD (n = 14) or 4 - 6 courses of EBVD/MOPP (mitoxin, oncovin, procarbazine, prednison; n = 21).
  • Chemotherapy was used as primary treatment thereby aiming to avoid radiotherapy with potential serious side effects to growing jaws and thyroid.
  • These three were salvaged with second-line chemotherapy without radiation therapy (RT) and are in second CR.
  • Moreover, it illustrates that although cure of pediatric NLPHL is feasible with chemotherapy only, high dosages of cytotoxic drugs are necessary as salvage treatment in a relatively high proportion of patients after relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Child. Dacarbazine / administration & dosage. Epirubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Recurrence. Remission Induction / methods. Retrospective Studies. Salvage Therapy / methods. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Aug;47(8):1450-1 [16966251.001]
  • (PMID = 16966260.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


6. Khoury JD, Jones D, Yared MA, Manning JT Jr, Abruzzo LV, Hagemeister FB, Medeiros LJ: Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol; 2004 Apr;28(4):489-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma.
  • The significance of bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma is unknown.
  • Of 275 patients diagnosed as lymphocyte predominant Hodgkin lymphoma at our institution (1983-2003), we identified 7 patients with purely nodular disease in the diagnostic lymph node biopsy specimen who also had bone marrow involvement.
  • The latter was detected at the time of initial diagnosis in four patients, after one cycle of chemotherapy in one patient, and at relapse in two patients.
  • All patients had laboratory, radiologic, and/or morphologic evidence of aggressive disease at the time of detection of bone marrow involvement.
  • At last follow-up, four patients had died of their disease and three were alive following therapy.
  • In conclusion, a small subset of patients in whom lymph node biopsy shows nodular lymphocyte predominant Hodgkin lymphoma with a purely nodular pattern also may have lymphoma in the bone marrow.
  • Although the best terminology for these bone marrow lymphomas is uncertain, the aggressive clinical behavior of these neoplasms supports the need for intensive therapy.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15087668.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Turk HM, Ozet A, Ozturk M, Komurcu S, Kuzhan O, Arpaci F, Ozturk B, Safali M: Isolated renal relapse of a case with non-Hodgkin's lymphoma. Med Oncol; 2010 Jun;27(2):434-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated renal relapse of a case with non-Hodgkin's lymphoma.
  • Transthoracic needle aspiration from the mass revealed findings consistent with nodular sclerosis variety of Hodgkin's disease.
  • Ultrasound guided renal biopsy revealed diffuse large B cell lymphoma.
  • Retrospective re-evaluation of the archival specimens of the mediastinal mass was also consistent with diffuse large B cell lymphoma.
  • After induction chemotherapy (four cycles of DHAP) she underwent high dose chemotherapy (BEAM) and autologous peripheral blood stem cell transplantation.
  • In conclusion, renal involvement during advanced lymphoma is quite common but isolated renal relapse in NHL is a rare situation.
  • Although renal infiltration generally shows a poor prognosis, long-term survival may be achieved with high dose chemotherapy and autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Jan;173(1):239 [15592087.001]
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):134-44 [7832273.001]
  • [Cites] Nephron Clin Pract. 2005;100(3):c86-91 [15824512.001]
  • [Cites] Urology. 1993 Sep;42(3):331-5 [8379037.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1733-8 [14692526.001]
  • [Cites] Hematol Oncol. 1990 Mar-Apr;8(2):105-10 [2344997.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2325-31 [8635103.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3783-5 [17704429.001]
  • [Cites] Turk J Pediatr. 1989 Jan-Mar;31(1):71-7 [2692261.001]
  • [Cites] Eur Urol. 1986;12(5):352-4 [3780803.001]
  • [Cites] Cancer. 1987 Aug 1;60(3):386-91 [3594375.001]
  • [Cites] Saudi J Kidney Dis Transpl. 2006 Sep;17(3):395-8 [16970262.001]
  • [Cites] Int Braz J Urol. 2006 Mar-Apr;32(2):190-2 [16650297.001]
  • [Cites] Clin Adv Hematol Oncol. 2008 Jul;6(7):527-31 [18654120.001]
  • [Cites] Tumour Biol. 2003 Aug-Sep;24(4):172-5 [14654710.001]
  • [Cites] Am J Nephrol. 1994;14(2):148-53 [8080008.001]
  • [Cites] Oncology. 1998 Sep-Oct;55(5):482-6 [9732229.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Apr;21(4):487-92 [4007017.001]
  • [Cites] Gen Diagn Pathol. 1997 Feb;142(3-4):147-53 [9065578.001]
  • [Cites] Eur J Haematol. 2001 Sep;67(3):158-64 [11737248.001]
  • [Cites] Am J Kidney Dis. 1994 Oct;24(4):586-9 [7942815.001]
  • [Cites] J Natl Med Assoc. 2003 Mar;95(3):220-4 [12749682.001]
  • [Cites] J Surg Oncol. 1997 Mar;64(3):207-11 [9121151.001]
  • [Cites] Br J Cancer. 1994 Jul;70(1):154-9 [7517172.001]
  • (PMID = 19437146.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Hall GW, Katzilakis N, Pinkerton CR, Nicolin G, Ashley S, McCarthy K, Daw S, Hewitt M, Wallace WH, Shankar A: Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report. Br J Haematol; 2007 Sep;138(6):761-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.
  • This report describes the clinical outcomes and follow-up records of 42 children with nodular lymphocyte predominant Hodgkin lymphoma (LPHL) treated on United Kingdom Children's Cancer Study Group (UKCCSG) HD1 (1982-1992) and HD2 protocols (1992-2000).
  • In both trials, only patients with stage IA disease had the option of being treated with either involved field radiation alone or combination chemotherapy consisting of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP).
  • Patients with all other stages were treated with ChlVPP chemotherapy.
  • Six children relapsed after primary therapy.
  • The 5- and 10-year relapse-free survival rates were 87% and 82% respectively.
  • In conclusion, children with low-stage LPHL treated between 1982 and 2000 according to the UK strategy for classical Hodgkin lymphoma (HL) had an excellent prognosis.
  • There have been no second malignancies or transformations to B-cell non-Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Chlorambucil / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Great Britain. Humans. Ireland. Male. Prednisone / therapeutic use. Procarbazine / therapeutic use. Prospective Studies. Recurrence. Remission Induction. Survival Rate. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760808.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; 35S93Y190K / Procarbazine; 5V9KLZ54CY / Vinblastine; VB0R961HZT / Prednisone; CHIVPP protocol
  •  go-up   go-down


9. Ansell SM, Armitage JO: Management of Hodgkin lymphoma. Mayo Clin Proc; 2006 Mar;81(3):419-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Hodgkin lymphoma.
  • Approximately 7350 new cases of Hodgkin lymphoma (HL) are diagnosed annually in the United States.
  • The disease is composed of 2 distinct entities: the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL.
  • Classical HL includes the subgroups nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte rich.
  • Selection of the appropriate therapy Is based on accurately assessing the stage of disease.
  • Patients with early-stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by Involved-field radiation therapy, whereas those with advanced-stage disease receive a longer course of chemotherapy without radiation therapy.
  • Although many patients respond well to initial therapies and have durable long-term remissions, a subset of patients has resistant disease and experiences relapse even after subsequent high-dose chemotherapy and autologous stem cell transplantation.
  • New therapies are clearly needed for these patients.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis. Salvage Therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529147.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


10. Saitoh T, Matsushima T, Yamane A, Sakuraya M, Irisawa H, Yokohama A, Handa H, Tsukamoto N, Karasawa M, Nojima Y, Murakami H: Hodgkin lymphoma accompanied by aplastic anemia and polyclonal expansion of large granular lymphocytes. Acta Haematol; 2007;117(4):238-41
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma accompanied by aplastic anemia and polyclonal expansion of large granular lymphocytes.
  • Immunologic abnormalities have been described in patients with Hodgkin lymphoma, including autoimmune hemolytic anemia and immune thrombocytopenic purpura.
  • The concurrent diagnoses of Hodgkin lymphoma and acquired aplastic anemia, however, is extremely rare.
  • We report a 56-year-old Japanese female patient with severe aplastic anemia and increased large granular lymphocytes prior to the recurrence of Hodgkin lymphoma.
  • After being in remission for 10 years from Hodgkin lymphoma, she developed progressive pancytopenia.
  • No lymphadenopathy was observed that would suggest a relapse of Hodgkin lymphoma.
  • A diagnosis of aplastic anemia was made, and treatment with corticosteroids and cyclosporine was initiated.
  • Two months later, she suddenly developed celiac and mediastinal lymphadenopathy.
  • She underwent one cycle of chemotherapy before she died of progressive pancytopenia.
  • Autopsy revealed the recurrence of Hodgkin lymphoma, nodular sclerosis in the lymph nodes and markedly hypocellular bone marrow.
  • Although autoimmune disorders are described in Hodgkin lymphoma, our case shows a rare instance of a patient who had aplastic anemia as the first manifestation of a relapse of Hodgkin lymphoma.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Transfusion. Female. Humans. Magnetic Resonance Imaging. Middle Aged


11. Harris MA, Radford JA, Deakin DP, James RD, Swindell R, Cowan RA: Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma. Clin Oncol (R Coll Radiol); 2004 Feb;16(1):53-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma.
  • AIMS: To analyse the treatment outcome for patients with stage I and II infra-diaphragmatic Hodgkin's lymphoma.
  • Twenty-five out of 33 patients received radiotherapy alone, three out of 33 patients received minimal initial chemotherapy (MIT) (4 weeks VAPEC B) and five patients received six cycles of ChlVPP EVA hybrid chemotherapy before radiotherapy.
  • Histological subtype was lymphocyte predominant (15/33), nodular sclerosis (11/33), mixed cellularity (4/33), lymphocyte-rich classical (1/33) and unclassifiable (2/33).
  • The 5-year overall survival was 89% and 5-year relapse-free survival was 85%.
  • The median time to relapse was 37 months (range 7-65 months).
  • All five relapses had received radiotherapy alone and four were salvaged with chemotherapy.
  • There have been four second malignancies and one patient transformed to high-grade non-Hodgkin's lymphoma.
  • No patient has died of Hodgkin's lymphoma.
  • CONCLUSIONS: In our cohort of patients with infra-diaphragmatic stage I and II Hodgkin's lymphoma treated with limited-field radiotherapy, no patients died from uncontrolled disease.
  • The use of MIT may reduce the risk of relapse and obviate the need for conventional salvage chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / radiotherapy. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Chlorambucil / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14768756.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 18D0SL7309 / Chlorambucil; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; ChlVPP-EVA regimen; VAPEC-B protocol
  •  go-up   go-down


12. Bashir H, Hudson MM, Kaste SC, Howard SC, Krasin M, Metzger ML: Pericardial involvement at diagnosis in pediatric Hodgkin lymphoma patients. Pediatr Blood Cancer; 2007 Oct 15;49(5):666-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial involvement at diagnosis in pediatric Hodgkin lymphoma patients.
  • BACKGROUND: Because most cases are clinically silent, the incidence, clinical course, and outcome of pericardial involvement in Hodgkin lymphoma are unknown.
  • METHODS: Records of all patients with newly diagnosed Hodgkin lymphoma treated at our institution between 1991 and 2004 were reviewed.
  • Pericardial involvement was identified by computerized tomography (CT) as focal thickening or nodularity present at the time of diagnosis, and by echocardiography as pericardial effusion.
  • Outcomes measured were incidence of pericardial involvement, relapse-free survival, and overall survival.
  • All patients with pericardial involvement had nodular sclerosing tumors versus 183 of 260 patients without pericardial involvement (P = 0.02); 9 (67%) had a bulky mediastinal mass versus 27% (P = 0.002).
  • In the 11 cases that did not undergo surgical drainage, the effusion resolved within days after starting chemotherapy.
  • Two patients experienced distant relapse but underwent successful salvage therapy.
  • CONCLUSIONS: Pericardial involvement by lymphoma is usually asymptomatic unless accompanied by substantial pericardial effusion.
  • In most cases, pericardial involvement resolves with treatment of the underlying malignancy, but close observation for hemodynamic complications is required.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Male. Neoplasm Metastasis. Pericardial Effusion. Pericardium / pathology. Recurrence. Retrospective Studies. Salvage Therapy. Survival Analysis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16874767.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA21765; United States / NCI NIH HHS / CA / R01-CA600419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Drach J, Kaufmann H, Woehrer S, Chott A, Zielinski CC, Raderer M: Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma.
  • : 6583 Background: Mantle cell lymphoma (MCL) remains difficult to treat by conventional treatment approaches.
  • Since the microenvironment plays an important role for growth and survival of malignant B-cells, we hypothesized that a treatment strategy targeting both the tumor cell and the microenvironment could be active in MCL.
  • R was administered at 375 mg/m<sup>2</sup> on days 1, 8, 15, and 22; THAL was given at a daily dose of 200mg starting on day 1 and a dose escalation to 400mg on day 15 (continued until progression or relapse).
  • RESULTS: 16 pts with MCL were treated (8 pts at first relapse including 2 pts after autologous transplantation, 5 pts at ≥ second relapse, 1 pt with primary CHOP-resistant MCL).
  • Median age of pts was 67 (range, 45 to 76) years, and time from initial diagnosis ranged between 6 and 53 (median, 21) months.
  • One pt experienced severe neutropenia associated with THAL causing discontinuation of treatment, and thromboembolic events were observed in 2 pts.
  • 13 of the 16 pts experienced an objective response (5 CR including the pt who failed to respond to CHOP and one pt at relapse after autotransplantation; 8 PR), one pt had SD.
  • Tumor responses occured both at nodular and extranodular MCL manifestations.
  • Median time to progression (TTP) was 20 months.
  • In pts achieving a CR, TTP was longer than the preceding TTP after chemotherapy (27+, 21, 20, 29 months versus 3, 15, 17, 22 months, respectively).
  • CONCLUSIONS: R+THAL has marked anti-tumor activity and low toxicity in pts with relapsed/resistant MCL, even after high-dose therapy.
  • Thus, a clinical trial with R-CHOP-THAL as frontline therapy for pts with MCL has been initiated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016180.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Barbounis A, Grigorakis V, Karkantaris C, Anargyrou K, Chatziioannou M, Rombos J, Boussiotis VA, Vaiopoulos G, Kittas C, Pangalis GA: Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol; 2001 Nov-Dec;67(5-6):279-88
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites.
  • BACKGROUND: Advanced Hodgkin's lymphoma (HL) is curable by conventional chemotherapy in 60--70% of patients.
  • The pretreatment identification of a sizeable subgroup of patients with sufficiently low failure-free survival (FFS) to be eligible for investigational treatment is necessary.
  • Most patients had nodular sclerosis (64%) and mixed cellularity (26%) histology.
  • Patients with greater-than-or-equals 5 involved sites and IPS greater-than-or-equals 3 had 10-yr FFS overall, and relapse-free survival of 41%, 45% and 49%, respectively.
  • [MeSH-minor] Adolescent. Adult. Aged. Antibiotics, Antineoplastic / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11872075.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


15. Jain S, Nigam S, Kumar N, Reddy BS: Cutaneous relapse in Hodgkin's disease: a case report. Acta Cytol; 2005 Mar-Apr;49(2):191-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous relapse in Hodgkin's disease: a case report.
  • CASE: A young male presented with multiple nodular lesions on the chest wall and matted cervical lymph nodes.
  • The cytologic diagnosis of Hodgkin's lymphoma was entertained and later confirmed on skin biopsy.
  • Past history revealed that the patient had been diagnosed with Hodgkin's disease and treated for it 2 years earlier, but had been lost to follow-up during treatment.
  • CONCLUSION: Cutaneous Hodgkin's disease should always be considered in smears from skin lesions showing atypical mononuclear cells in a polymorphous background, even in the absence of a definitive clinical diagnosis at the time of presentation.
  • [MeSH-minor] Adult. Biopsy, Needle. Disease Progression. Drug Therapy. Humans. Leukocytes, Mononuclear / pathology. Lymph Nodes / pathology. Male. Prognosis. Recurrence

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15839627.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Molin D: Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. Ups J Med Sci; 2004;109(3):179-228
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis.
  • Hodgkin lymphoma (HL) is characterised histologically by a minority of malignant Hodgkin and Reed-Sternberg (HRS) cells surrounded by benign cells, and clinically by a relatively good prognosis.
  • The treatment, however, leads to a risk of serious side effects.
  • Knowledge about the biology of the disease, particularly the interaction between the HRS cells and the surrounding cells, is essential in order to improve diagnosis and treatment.
  • It correlated to number of tumour eosinophils, nodular sclerosis (NS) histology, and the negative prognostic factors high erythrocyte sedimentation rate (ESR) and blood leukocyte count (WBC).
  • The number of mast cells in HL tumours correlated to worse relapse-free survival, NS histology, high WBC, and low blood haemoglobin.
  • Survival in patients with early and intermediate stage HL, diagnosed between 1985 and 1992, was generally favourable and comparatively limited treatment was sufficient to produce acceptable results for most stages.
  • Patients treated with a short course of chemotherapy and radiotherapy had an excellent outcome.


17. Okawa Y, Shimada T, Nagasaki E, Nozato A, Mizoroki F, Kobayashi M: [Pulmonary cryptococcosis occurring 6 months after cladribine therapy for relapsed follicular lymphoma]. Rinsho Ketsueki; 2006 Jul;47(7):650-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary cryptococcosis occurring 6 months after cladribine therapy for relapsed follicular lymphoma].
  • We report a case of follicular lymphoma in which pulmonary cryptococcosis occurred with cladribine therapy.
  • He was diagnosed as having follicular lymphoma, grade 1, clinical stage IVA from a tongue tumor biopsy in January 2003.
  • A total of 6 courses of R-CHOP therapy was performed, but no clear effect was found.
  • A new cervical lesion appeared, so he was treated with a total of 2 courses of R-EPOCH therapy, and the effect was classed as stable disease.
  • We started cladribine therapy (0.09 mg/kg, seven days of continuous infusion) from February 2004, and complete remission was achieved after 4 courses of cladribine therapy.
  • In January 2005, an abnormal nodular shadow in the right S10 area was found on chest CT images which was diagnosed as pulmonary cryptococcosis by serum antigen and a trans-bronchial lung biopsy.
  • Afterward, the fifth course of cladribine therapy and local radiation therapy were performed against a relapse of lymphoma, but cryptococcosis did not reappear.
  • The prolonged bone marrow suppression after cladribine therapy was considered to be a severe adverse event.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cladribine / adverse effects. Cryptococcosis / etiology. Lung Diseases, Fungal / etiology. Lymphoma, Follicular / drug therapy. Opportunistic Infections
  • [MeSH-minor] Bone Marrow / drug effects. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cryptococcosis.
  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910576.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


18. Móciková H, Konífrová E, Stríteský J: [Serious cutaneous toxicity following ifosfamide, gemcitabine and vinorelbine therapy in a patient with relapsed Hodgkin lymphoma and ichthyosis]. Cas Lek Cesk; 2009;148(9):434-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serious cutaneous toxicity following ifosfamide, gemcitabine and vinorelbine therapy in a patient with relapsed Hodgkin lymphoma and ichthyosis].
  • Nodular sclerosis classical Hodgkin lymphoma, clinical stage IIB with cervical and axillar lymph node involvement was histologically proven in a 47-year-old male patient with a long-lasting history of ichthyosis.
  • Patient was treated with six cycles of combined chemotherapy: doxorubicin, bleomycin, vinblastine and dacarbazine.
  • 15 months after initial treatment the first relapse of Hodgkin lymphoma was histologically confirmed and involvement of lymph nodes was identical with initial staging.
  • Patient was successfully treated with six cycles of chemotherapy: ifosfamide, carboplatinum and etoposide followed by radiotherapy.
  • 4 years after previous therapy the second relapse of Hodgkin lymphoma occurred with axillar and inguinal lymph node involvement.
  • Patient was treated with three cycles of combined chemotherapy: ifosfamide, gemcitabine, vinorelbine and prednisone.
  • This chemotherapy caused neutropenia WHO grade 4 after each cycle and a serious diffuse toxoallergic cutaneous reaction with bullous erythema developed.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Drug Eruptions / etiology. Hodgkin Disease / drug therapy. Ichthyosis / complications. Ifosfamide / adverse effects. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Ichthyosis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899733.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


19. Provencio M, España P, Millán I, Sánchez A, Cantos B, Bonilla F: The management of stage I-II supradiaphragmatic Hodgkin's disease with chemotherapy alone. Leuk Lymphoma; 2003 Feb;44(2):263-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of stage I-II supradiaphragmatic Hodgkin's disease with chemotherapy alone.
  • The treatment of choice for patients with early stage Hodgkin's disease (HD) has been extended field or subtotal nodal irradiation.
  • Remission rates of over 95% have been obtained, however, about 5% of stage I and II patients will suffer from progressive disease while on therapy and an additional 15-20% will relapse.
  • Chemotherapy (Ch) alone has not been adequately tested in early-stage HD.
  • Three (8.5%) patients died: two due to a second tumour (non-Hodgkin's lymphoma and myeloid acute leukaemia) and the other due to sepsis post-Ch.
  • Univariate and multivariate analysis only associated histology subtype relative risk (RR) 4.0 nodular sclerosis (95% IC, 1.0-5.5; p:0.02) with higher relapse.
  • Outside clinical trials due to the lack of clear prognostic factors, with the exception of specific situations, patients should be informed of all the possible alternatives as well as the consequences of the treatments employed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12688343.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Balwierz W, Klekawka T, Moryl-Bujakowska A, Matysiak M, Sopyło B, Wachowiak J, Kaczmarek-Kanold M, Sońta-Jakimczyk D, Janik-Moszant A, Chybicka A, Chaber R, Kowalczyk JR, Mitura-Lesiuk M, Balcerska A, Stachowicz-Stencel T, Wysocki M, Kołtan A, Krawczuk-Rybak M, Muszyńska-Rosłan K, Młynarski W, Stolarska M, Sobol G, Wieczorek M, Karolczyk G, Urbanek-Dadela A: [Can children with Hodgkin's disease be treated with chemotherapy only?]. Przegl Lek; 2010;67(6):375-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Can children with Hodgkin's disease be treated with chemotherapy only?].
  • [Transliterated title] Czy dzieci z choroba Hodgkina moga być leczone wyłacznie chemioterapia?
  • Currently over 90% of children and adolescents with Hodgkin's disease (HD) can be cured thanks to use of multidrug chemotherapy (CT) combined with involved-field radiotherapy (IF-RT).
  • However, the intensive treatment may increase the risk of late complications which may impair the patients' quality of life.
  • In order to decrease the incidence of late complications the protocol with limited use of IF-RT was introduced in centers of Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG).
  • This study presents the treatment results of patients treated with CT only in comparison with the therapy results of children treated with CT and IF-RT.
  • In 45 patients with IA-IIA stages presenting favorable risk factors (small mediastinal tumor, peripheral nodular mass of a maximum diameter < 6 cm, involvement of less than three nodular regions, ESR < 50 mm after 1 h, histologic type other than lymphocyte depletion and very good treatment response assessed after 3 CT cycles) IF-RT was omitted.
  • The rates of 5-year overall survival (OS), relapse-free survival (RFS) and event-free survival (EFS) were 97%, 96% i 92%, respectively.
  • Our results show that the use of CT only in precisely selected group of patients with HD do not impair the treatment results and may decrease the risk of late life threatening complications.
  • Treatment response assessment with the use of PET may in future increase the number of patients treated without RT and limit the need of the use of invasive diagnostic methods in patients with residual mass.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21344765.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


21. Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Bettacchi A, Mulattieri S, Picardi P, Tassetti A, Scortechini AR, Fioritoni G, Leoni P: Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies. Eur J Haematol; 2009 Mar;82(3):184-93
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies.
  • OBJECTIVES: The therapy of advanced, relapsed or refractory primary cutaneous lymphomas is often unsatisfactory.
  • Recent data indicate a favourable pharmacokynetic, pharmacodynamic and toxicity profile of pegylated liposomal doxorubicin (Peg-Doxo) in primary cutaneous T-cell lymphomas, while in primary cutaneous B-cell lymphomas (PCBCLs), the drug efficacy has never been assessed so far.
  • One patient had a marginal zone B-cell lymphoma and four were affected by diffuse large B-cell lymphoma-leg type, all with widespread nodular lesions.
  • RESULTS: All the patients achieved a complete response (CR = 100%) in a short period of time (median 3 months), even when pretreated with radio-chemotherapy.
  • Two experienced a relapse.
  • As concerning the toxicity profile, the treatment was well-tolerated, no one decreased or delayed the dose.
  • CONCLUSIONS: In spite of the small number of patients, it emerges that monochemotherapy with Peg-Doxo has a significantly high clinical activity and a good safety profile in PCBCLs, even in aggressive forms, compared with other therapeutic regimens, which are completely reviewed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Doxorubicin / analogs & derivatives. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Polyethylene Glycols / adverse effects. Polyethylene Glycols / therapeutic use. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215609.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


22. Coleman M, Kaufmann T, Nisce LZ, Leonard JP: Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1235-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation.
  • PURPOSE: At the New York Presbyterian Hospital-Cornell Medical Center, patients with unequivocal clinical stage I and IIA Hodgkin's disease (HD) have been treated with mantle, splenic, and extended field radiation therapy (EFRT) (without surgical staging).
  • Patients with pathological or equivocal staging, "B" symptoms, bulk disease, history of previous chemotherapy, and/or Stage III or IV disease were excluded from our analysis.
  • Nine of the relapses had nodular sclerosis histology, one had lymphocyte predominance, and none had mixed cellularity.
  • The median time to relapse was 38 months; mean time 42. 3 months.
  • All patients are alive, well and free of disease, including nine who received subsequent chemotherapy and one who underwent autotransplantation.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10725636.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 07968
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


23. Krásný J, Sach J, Brunnerová R, Konvicka J, Jankovská M, Srp A, Kozák J: [Orbital tumors in adults--a 10-year study]. Cesk Slov Oftalmol; 2008 Nov;64(6):219-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors refer about diagnostic procedures, treatment and follow-up of 87 adult patients with orbital tumors during the period 1998 - 2007 in the Department of Ophthalmology, Faculty Hospital Královské Vinohrady, Charles University, Prague, Czech Republic, E.U.
  • The anterior diagnostic or therapeutic orbitotomy was used in 72.5% of the cases, lateral osteoplastic orbitotomy (Kronlein) in 14.5%, and exenteration of the orbit in 13% of the cases.
  • Clinically they were of the anterior nodular, or posterior diffuse form, dacryoadenitis or orbital myositis.
  • All patients were treated by means of prednisolon for at least three months; due to the relapse of the immunopathologic process, in 16 % of the cases the therapy was supplemented with azathioprime.
  • The surgical procedure was the choice of treatment in 66% of inflammatory processes in the lacrimal gland region.
  • In four cases the sarcoidosis was established.The second tumor in the final ranking was lymphoma in 19.5%; the MALT-lymphoma was diagnosed in 59% of these cases.
  • The chemotherapy was chosen for the treatment in 2/3 of the cases, and in all cases the remission was reached.The actinotherapy was chosen especially in other types of lymphoma; the follicular form and "molding" lymphoma were the causes of the death in two patients.
  • CONCLUSION: Among orbital tumors in adults, the most common were inflammatory pseudotumor and lymphoma.
  • The decisive procedure was always the histological verification, which directed the following therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110961.001).
  • [ISSN] 1211-9059
  • [Journal-full-title] Ceská a slovenská oftalmologie : casopis Ceské oftalmologické spolecnosti a Slovenské oftalmologické spolecnosti
  • [ISO-abbreviation] Cesk Slov Oftalmol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


24. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P: Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results. Ann Oncol; 2005 Dec;16(12):1936-40
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results.
  • In order to minimize chemotherapy toxicity and avoid eventual hospitalization and psychological and financial burdens we have applied since 1988, for the first time in Iran, a treatment regimen based on subsequently revised DAL-HD 85-90 and later GPOH-HD 95 protocols.
  • PATIENTS AND METHODS: During the period 1988-2004, 40 children with HD received DAL/GPOH-HD-adapted treatment; 25 males (62.5%) and 15 females (37.5%) (male/female ratio 1.7; age 4-14 years, mean 8.8).
  • Histopathology: 22 patients had mixed cellularity (MC; 55%), 13 nodular sclerosis (32.5%), four lymphocyte predominance (LP; 10%) and one patient lymphocyte depletion (2.5%).
  • Twenty nine patients (72.5%) received radiotherapy (20-25 Gy); four to the involved field (stage I), 25 to the upper mantel (stage II and also III with either residual or mediastinal mass) and three additionally to spleen and para-aortic lymph nodes.
  • Eleven patients received only chemotherapy.
  • Relapse occurred in eight patients (20%); seven stage IV (MC) and one stage IA (LP) with progression to IIIB.
  • Salvage chemotherapy consisted of MOPP/ABVD hybrid; six patients achieved a second sustained remission and three patients died: two due to relapse and progressive disease and the third one in CR, owing to thrombocytopenic hemorrhage and foudroyant pneumonia.
  • Aside from minor acute toxicities, three patients demonstrated azoospermia at the age of 18 years and one of these patients suffered non-Hodgkin lymphoma as a second malignancy.
  • Both received appropriate treatment and are over 10 years in CR.
  • CONCLUSIONS: The DAL/GPOH-HD-based treatment approach proved to achieve long-term sustained cure even in children with advanced HD disease.
  • The essentially outpatient diagnosis and treatment modus did not compromise the disease outcome, and was well tolerated and accepted by the patients and their parents.
  • The employed drugs are easily available and affordable.
  • This treatment approach is suitable for ambulatory use in developing countries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157620.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Vora A, Mitchell CD, Lennard L, Eden TO, Kinsey SE, Lilleyman J, Richards SM, Medical Research Council, National Cancer Research Network Childhood Leukaemia Working Party: Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet; 2006 Oct 14;368(9544):1339-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: 6-mercaptopurine has been a standard component of long-term continuing treatment for childhood lymphoblastic leukaemia, whereas 6-thioguanine has been mainly used for intensification courses.
  • Since preliminary data have shown that 6-thioguanine is more effective than 6-mercaptopurine, we compared the efficacy and toxicity of the two drugs for childhood lymphoblastic leukaemia.
  • METHODS: Consecutive children with lymphoblastic leukaemia diagnosed in the UK and Ireland between April, 1997, and June, 2002, were randomly assigned either 6-thioguanine (750 patients) or 6-mercaptopurine (748 patients) during interim maintenance and continuing therapy.
  • FINDINGS: After a median follow up of 6 years, there was no difference in event-free or overall survival between the two treatment groups.
  • Although 6-thioguanine conferred a significantly lower risk of isolated CNS relapse than did 6-mercaptopurine (odds ratio [OR] 0.53, 95% CI 0.30-0.92, p=0.02), the benefit was offset by an increased risk of death in remission (2.22, 1.20-4.14, p=0.01), mainly due to infections during continuing therapy.
  • Additionally, 95 patients developed veno-occlusive disease of the liver.
  • On long-term follow-up, about 5% of 6-thioguanine recipients have evidence of non-cirrhotic portal hypertension due to periportal liver fibrosis or nodular regenerative hyperplasia.
  • 6-mercaptopurine should remain the thiopurine of choice for continuing therapy of childhood lymphoblastic leukaemia.
  • [MeSH-major] 6-Mercaptopurine / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thioguanine / therapeutic use


26. Jiang YG, Chen JH, Jiang R, Hang G, Wang GH, Wang D, Li FC, Liu H, Shi CJ, Wu HJ, Yuan YG: [Testicular tumor in Mongolian men (report of 35 cases)]. Zhonghua Nan Ke Xue; 2006 May;12(5):397-400
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To improve the diagnosis, therapy and prognosis of testicular tumor in Mongolian men.
  • RESULTS: The usual presentation of a testicular tumor was a nodular or painless swelling of one gonad.
  • The histologic composition of this series was 21 (60%) seminoma, 10 (28.6%) nonseminoma, 2 (5.7%) lymphoma, 1 (2.35%) fibroneuroma and 1 (2.35%) leiomyoma.
  • Combined therapy, including radical orchiectomy, radiotherapy and chemotherapy, were taken.
  • 29 cases have been followed for 2 months to 10 years, 4 out of them died of distant metastasis, one died of other disease, one lives with tumor, the others live without relapse and metastasis.
  • Better public awareness regarding testicular tumor in this population, advances in diagnosis and therapy will help to improve therapeutic effectiveness and prognosis.
  • [MeSH-major] Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child, Preschool. Combined Modality Therapy. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755865.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  •  go-up   go-down






Advertisement